The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection.

[1]  E. Richtig,et al.  Does the time interval between sentinel lymph node biopsy and completion lymph node dissection affect outcome in malignant melanoma? A retrospective cohort study. , 2020, International journal of surgery.

[2]  C. Garbe,et al.  Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. , 2019, European journal of cancer.

[3]  C. Berking,et al.  Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  V. Sondak,et al.  Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit , 2019, Journal of surgical oncology.

[5]  A. Hauschild,et al.  Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. van Klaveren,et al.  Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. , 2018, European journal of cancer.

[7]  P. Ascierto,et al.  Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). , 2018 .

[8]  C. Berking,et al.  Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node. , 2018 .

[9]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[10]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[11]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[12]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[13]  F. Hodi,et al.  Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.

[14]  A. Gesierich,et al.  Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma , 2017, The New England journal of medicine.

[15]  A. Testori,et al.  Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma , 2017, The British journal of surgery.

[16]  A. Eggermont,et al.  The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  A. Hauschild,et al.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.

[18]  Susan Halabi,et al.  American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine , 2016, CA: a cancer journal for clinicians.

[19]  C. Berking,et al.  Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[20]  R. Dummer,et al.  Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. , 2016, European Journal of Cancer.

[21]  Martha Sajatovic,et al.  Clinical Prediction Models , 2013 .

[22]  D. Schadendorf,et al.  Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[24]  R. Gutzmer,et al.  Age as a key factor influencing metastasizing patterns and disease‐specific survival after sentinel lymph node biopsy for cutaneous melanoma , 2011, International journal of cancer.

[25]  I. V. D. van der Ploeg,et al.  Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Scolyer,et al.  Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Eggermont,et al.  Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients: A Multicenter Study in 388 Patients With Positive Sentinel Nodes , 2008, Annals of surgery.

[29]  Jeffrey E. Lee,et al.  Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Roulin,et al.  Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[31]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[32]  D. Morton,et al.  Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Mark,et al.  Clinical prediction models: are we building better mousetraps? , 2003, Journal of the American College of Cardiology.

[34]  Frank E. Harrell,et al.  Prediction models need appropriate internal, internal-external, and external validation. , 2016, Journal of clinical epidemiology.